Melanoma Clinical Trials in Boston

Showing 201-219 of 219 trials

Cabozantinib-S-Malate and Vemurafenib in Treating Patients With Solid Tumors or Melanoma That is Metastatic or That Cannot Be Removed By Surgery

NCT01835184

This phase I trial studies the side effects and best dose of cabozantinib-s-malate when given together with vemurafenib in treating patients with solid tumors or melanoma that is metastatic or that cannot be removed by surgery. Cabozantinib-s-malate and vemurafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Recurrent MelanomaStage IIIA MelanomaStage IIIB Melanoma+3 more

National Cancer Institute (NCI)5 participantsStarted May 2013

Atlanta, Georgia, United States • Boston, Massachusetts, United States • Richmond, Virginia, United States

COMPLETEDPhase 2< 1 mile

Evaluation of Tumor Response to Ipilimumab in the Treatment of Melanoma With Brain Metastases

NCT00623766

To assess the response of melanoma with brain metastases to ipilimumab treatment while maintaining acceptable tolerability.

Melanoma

Bristol-Myers Squibb99 participantsStarted Jul 2008

Scottsdale, Arizona, United States • Duarte, California, United States • Los Angeles, California, United States +11 more locations

Cabozantinib-S-Malate and Vemurafenib in Treating Patients With Solid Tumors or Melanoma That is Metastatic or That Cannot Be Removed By Surgery

Evaluation of Tumor Response to Ipilimumab in the Treatment of Melanoma With Brain Metastases

Melanoma Trials in Other Cities

Elesclomol (STA-4783) With Paclitaxel Versus Paclitaxel Alone in Melanoma

Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Stage III or Stage IV Melanoma

Boron Neutron Capture Therapy in Treating Patients With Stage III Melanoma

Vaccine Therapy With High-Dose Interleukin-2 in Treating Patients With Metastatic Melanoma

Interferon Alfa and Thalidomide in Treating Patients With Stage IV Melanoma

S9804: Vinorelbine in Treating Patients With Stage IV Melanoma

Study of CP-675,206 in Refractory Melanoma

A Study of Volociximab in Metastatic Melanoma

SWOG-9430: Surgery in Treating Patients With Metastatic Melanoma

Combination of Anti-CD137 & Ipilimumab in Patients With Melanoma

Trial of Dacarbazine With or Without Genasense in Advanced Melanoma

Vaccine Therapy for Patients With Stage IV Melanoma

STA-4783/Paclitaxel or Paclitaxel Alone in Melanoma

Study of Ipilimumab (MDX-010) Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma

CP-675,206 Versus Either Dacarbazine Or Temozolomide In Patients Without Prior Therapy

Multicentre, Dose Finding, Ph II,CP-4055 in Comb. With Sorafenib - Patients With Metastatic Malignant Melanoma

SciBase International Melanoma Pivotal Study

Other Conditions in Boston